LGALS3 and melanoma: LAG-3, along with its ligands Galectin-3 and HLA-II, was found to be particularly expressed in melanoma lesions with inflamed T-cell phenotypes such as high-risk uveal melanoma, where Gal-3/LAG-3 interplay restricts T-cell-mediated responses [34].